Palatin Technologies, Inc. (LON:0KF3)
London flag London · Delayed Price · Currency is GBP · Price in USD
23.01
+0.13 (0.57%)
At close: Mar 6, 2026

Palatin Technologies Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.

It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.

The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.

Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Palatin Technologies, Inc.
Country United States
Founded 1986
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 29
CEO Carl Spana

Contact Details

Address:
11 Deer Park Drive
Monmouth Junction, New Jersey 08512
United States
Phone 609 495 2200
Website palatin.com

Stock Details

Ticker Symbol 0KF3
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year July - June
Reporting Currency USD
ISIN Number US6960776010
SIC Code 2836

Key Executives

Name Position
Dr. Carl Spana Ph.D. Co-Founder, President, Chief Executive Officer and Director
Stephen T. Wills CPA, MST Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Burns McClellan Vice President of Investor Relations
Stephen A. Slusher Esq. Chief Legal Officer
Dr. Michael B. Raizman M.D. Chief Medical Officer
James E. Hattersley B.A., M.S. Senior Vice President of Business Development
John Dodd Ph.D. Senior Vice President of Preclinical Development
Robert Jordan Senior Vice President of Program Operations